Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

10.08
-0.2100-2.04%
Post-market: 10.150.0700+0.69%19:53 EST
Volume:1.11M
Turnover:11.38M
Market Cap:616.26M
PE:-6.33
High:10.54
Open:10.11
Low:10.05
Close:10.29
52wk High:35.34
52wk Low:10.05
Shares:61.14M
Float Shares:49.91M
Volume Ratio:1.44
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5922
EPS(LYR):-1.8336
ROE:-10.58%
ROA:-8.69%
PB:0.68
PE(LYR):-5.50

Loading ...

Janux Therapeutics Cut to Peer Perform from Outperform by Wolfe Research

Dow Jones
·
Nov 12

Piper Sandler Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)

TIPRANKS
·
Nov 10

UBS Reaffirms Their Hold Rating on Janux Therapeutics Inc (JANX)

TIPRANKS
·
Nov 10

NASDAQ Net Change Percentage Gainers & Losers

Dow Jones
·
Nov 10

Janux Reports Deep B-Cell Depletion in Initial Phase 1 Trial of JANX011; Shares Fall

MT Newswires Live
·
Nov 09

Janux Therapeutics - Janx011 Shows Selective Trbv6 T-Cell Activation Supporting Arm Platform Design

THOMSON REUTERS
·
Nov 09

Janux Therapeutics - Only Grade 1 Cytokine Release Syndrome Events; no Serious Adverse Events Reported

THOMSON REUTERS
·
Nov 09

Janux Therapeutics Announces Positive Initial Phase 1 Data for Janx011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease

THOMSON REUTERS
·
Nov 09

Janux Therapeutics (JANX) Earnings Beat Puts Its Pricey Valuation Back In Focus

Simply Wall St.
·
Nov 08

Janux: Depressed Valuation and Upcoming Clinical Catalysts Support Buy Rating

TIPRANKS
·
Nov 07

Minerva Neurosciences Posts Q3 Profit on Non-Cash Warrant Gain

Reuters
·
Nov 06

Soligenix Q3 Net Loss Narrows on Lower R&D Costs

Reuters
·
Nov 06

Wedbush Raises Price Target on Janux Therapeutics to $40 From $36, Keeps Outperform Rating

MT Newswires Live
·
Nov 06

Janux Therapeutics, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary

Reuters
·
Nov 06

Janux Therapeutics Q3 Net Loss Narrows on Lower R&D Expenses

Reuters
·
Nov 06

Janux Therapeutics Q3 EPS $(0.34) Beats $(0.46) Estimate, Sales $9.290M Beat $7.746M Estimate

Benzinga Earnings
·
Nov 06

Janux Therapeutics Q3 Basic EPS USD -0.34

Reuters
·
Nov 06

Janux Therapeutics Q3 Collaboration Revenue USD 9.289 Million

THOMSON REUTERS
·
Nov 06

Press Release: Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Dow Jones
·
Nov 06

Janux Therapeutics options imply 18.2% move in share price post-earnings

TIPRANKS
·
Nov 06